Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Midkine Promotes Metastasis and Therapeutic Resistance via mTOR/RPS6 in Uveal Melanoma. (2022) Karg M, John L, Refaian N, Büttner C, Rottmar T, Sommer J, Bock B, et al. Journal article The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. (2022) Rejeski K, Perez A, Iacoboni G, Penack O, Bucklein V, Jentzsch L, Mougiakakos D, et al. Journal article CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma (2021) Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, et al. Journal article BNT211: A phase I/II trial to evaluate safety and efficacy of CLDN6 CAR-T cells and CARVac-mediated in vivo expansion in patients with CLDN6+advanced solid tumors (2021) Haanen J, Mackensen A, Koenecke C, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution An easily expandable multi-drug LC-MS assay for the simultaneous quantification of 57 oral antitumor drugs in human plasma (2021) Kehl N, Schlichtig K, Dürr P, Bellut L, Dörje F, Fietkau R, Pavel ME, et al. Journal article Lymphocyte Immune Response and T Cell Differentiation in Fontan Patients with protein-losing enteropathy (2021) Moosmann J, Toka O, Lukassen S, Ekici AB, Mackensen A, Dittrich S, Völkl S Journal article The CAR- Hematotox Identifies Patients at High Risk for Prolonged Neutropenia, Infectious Complications and Prolonged Hospitalization Following CD19-CART in R/R LBCL (2021) Rejeski K, Perez-Perez A, Iacoboni G, Penack O, Buecklein VL, Jentzsch L, Mougiakakos D, et al. Conference contribution A Phase I Open Label Dose Escalation Study of MB-CART19.1 in Relapsed and Refractory CD19+B Cell Malignancies, Interim Preliminary Results in Pediatric ALL, Adult ALL Including CLL Cohorts (2021) Mackensen A, Hanssens L, Stelljes M, Bethge WA, Feuchtinger T, Kuenkele A, Aigner M, et al. Conference contribution BNT211: A PHASE I/II TRIAL TO EVALUATE SAFETY AND EFFICACY OF CLDN6 CAR-T CELLS AND VACCINE-MEDIATED IN VIVO EXPANSION IN PATIENTS WITH CLDN6-POSITIVE ADVANCED SOLID TUMORS (2021) Mackensen A, Koenecke C, Haanen J, Alsdorf W, Desuki A, Wagner-Drouet E, Heudobler D, et al. Conference contribution Variable expression of the disialoganglioside gd2 in breast cancer molecular subtypes (2021) Erber R, Kailayangiri S, Hübner H, Rübner M, Hartmann A, Häberle L, Meyer J, et al. Journal article